English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsVivimed labs

    Vivimed Labs

    Jump to
    • Vivimed Labs Standalone March 2025 Net Sales at Rs 22.58 crore, down 37.95% Y-o-Y

      Vivimed Labs Standalone March 2025 Net Sales at Rs 22.58 crore, down 37.95% Y-o-Y

    • Vivimed Labs Consolidated March 2025 Net Sales at Rs 25.61 crore, down 33.67% Y-o-Y

      Vivimed Labs Consolidated March 2025 Net Sales at Rs 25.61 crore, down 33.67% Y-o-Y

    • Vivimed Labs Consolidated December 2024 Net Sales at Rs 36.51 crore, down 11.94% Y-o-Y

      Vivimed Labs Consolidated December 2024 Net Sales at Rs 36.51 crore, down 11.94% Y-o-Y

    • Vivimed Labs Standalone December 2023 Net Sales at Rs 37.14 crore, down 26.55% Y-o-Y

      Vivimed Labs Standalone December 2023 Net Sales at Rs 37.14 crore, down 26.55% Y-o-Y

    • Vivimed Labs Consolidated September 2023 Net Sales at Rs 33.64 crore, down 23.93% Y-o-Y

      Vivimed Labs Consolidated September 2023 Net Sales at Rs 33.64 crore, down 23.93% Y-o-Y

    • Vivimed Labs Standalone June 2023 Net Sales at Rs 33.00 crore, down 30.33% Y-o-Y

      Vivimed Labs Standalone June 2023 Net Sales at Rs 33.00 crore, down 30.33% Y-o-Y

    • Vivimed Labs Consolidated June 2023 Net Sales at Rs 35.35 crore, down 29.45% Y-o-Y

      Vivimed Labs Consolidated June 2023 Net Sales at Rs 35.35 crore, down 29.45% Y-o-Y

    • Vivimed Labs Consolidated March 2023 Net Sales at Rs 37.03 crore, down 39.43% Y-o-Y

      Vivimed Labs Consolidated March 2023 Net Sales at Rs 37.03 crore, down 39.43% Y-o-Y

    • Vivimed Labs Standalone March 2023 Net Sales at Rs 39.72 crore, down 25.23% Y-o-Y

      Vivimed Labs Standalone March 2023 Net Sales at Rs 39.72 crore, down 25.23% Y-o-Y

    • Vivimed Labs Consolidated December 2022 Net Sales at Rs 55.74 crore, down 1.38% Y-o-Y

      Vivimed Labs Consolidated December 2022 Net Sales at Rs 55.74 crore, down 1.38% Y-o-Y

    • Vivimed Labs Standalone December 2022 Net Sales at Rs 50.56 crore, down 2.59% Y-o-Y

      Vivimed Labs Standalone December 2022 Net Sales at Rs 50.56 crore, down 2.59% Y-o-Y

    • Vivimed Labs Consolidated September 2022 Net Sales at Rs 44.22 crore, down 18.67% Y-o-Y

      Vivimed Labs Consolidated September 2022 Net Sales at Rs 44.22 crore, down 18.67% Y-o-Y

    • Vivimed Labs Standalone March 2022 Net Sales at Rs 53.12 crore, up 53.19% Y-o-Y

      Vivimed Labs Standalone March 2022 Net Sales at Rs 53.12 crore, up 53.19% Y-o-Y

    • Vivimed Labs Standalone March 2022 Net Sales at Rs 53.12 crore, up 53.19% Y-o-Y

      Vivimed Labs Standalone March 2022 Net Sales at Rs 53.12 crore, up 53.19% Y-o-Y

    • Vivimed Labs Consolidated March 2022 Net Sales at Rs 61.13 crore, up 56.78% Y-o-Y

      Vivimed Labs Consolidated March 2022 Net Sales at Rs 61.13 crore, up 56.78% Y-o-Y

    • Vivimed Labs Standalone December 2021 Net Sales at Rs 51.90 crore, down 16.87% Y-o-Y

      Vivimed Labs Standalone December 2021 Net Sales at Rs 51.90 crore, down 16.87% Y-o-Y

    • Vivimed Labs Consolidated December 2021 Net Sales at Rs 56.52 crore, down 79.66% Y-o-Y

      Vivimed Labs Consolidated December 2021 Net Sales at Rs 56.52 crore, down 79.66% Y-o-Y

    • Bulk Deals | Equity Intelligence India buys 1% stake in Cupid; Plutus Capital raises holding in Mohini Health

      Bulk Deals | Equity Intelligence India buys 1% stake in Cupid; Plutus Capital raises holding in Mohini Health

      Among other deals, Sunidhi Securities & Finance acquired 10 lakh equity shares of Pricol at Rs 94.05 per share, while Alpha Leon Enterprises LLP purchased 4,22,237 equity shares of Vivimed Labs at Rs 22.65 per share.

    • Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India

      Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India

      Vivimed Labs in receipt of Government of India (DGHS) approval to manufacture and market Favipiravir tablets in the strengths of 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India, the company said in a regulatory filing.

    • Vivimed Labs shares hit upper circuit on govt nod to manufacture, market Favipiravir tablet to treat COVID-19

      Vivimed Labs shares hit upper circuit on govt nod to manufacture, market Favipiravir tablet to treat COVID-19

      Vivimed Labs received Government of India approval to manufacture and market Favipiravir Tablet 200 mg & 400 mg under brand name “Favulous” across India. It is used for the treatment of mild to moderate cases of Covid-19, the company said.

    • Vivimed Labs shares surge 20% on approvals for 3 products

      Vivimed Labs shares surge 20% on approvals for 3 products

      The share touched a 52-week high of Rs 23.62 and a 52-week low of Rs 9.70 on 25 August, 2020 and 27 May, 2020, respectively.

    • Vivimed Labs Standalone December 2020 Net Sales at Rs 62.44 crore, down 0.53% Y-o-Y

      Vivimed Labs Standalone December 2020 Net Sales at Rs 62.44 crore, down 0.53% Y-o-Y

    • Vivimed Labs share price up nearly 5% on approval of products

      Vivimed Labs share price up nearly 5% on approval of products

      The share gained 41 percent in the last 9 months.

    • Vivimed Labs Consolidated June 2019 Net Sales at Rs 344.21 crore, down 4% Y-o-Y

      Vivimed Labs Consolidated June 2019 Net Sales at Rs 344.21 crore, down 4% Y-o-Y

    • Vivimed Labs Standalone June 2019 Net Sales at Rs 59.11 crore, down 4.64% Y-o-Y

      Vivimed Labs Standalone June 2019 Net Sales at Rs 59.11 crore, down 4.64% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347